Global Point of Care Lipid Test Market - 2025 -2033
Point-of-Care (POC) Lipid Test Market Size and Trends
The global point-of-care (POC) lipid test market reached US$ 0.68 billion in 2023, with a rise to US$ 0.72 billion in 2024, and is expected to reach US$ 1.23 billion by 2033, growing at a CAGR of 6.8% during the forecast period 2025–2033. The growing emphasis on preventive healthcare, decentralized diagnostics, and patient-centered care is reshaping the point-of-care (POC) lipid test market, as rapid testing solutions become increasingly vital for managing cardiovascular risk. By delivering immediate, reliable results outside traditional laboratories, POC lipid tests empower clinicians, pharmacists, and patients to make faster and more informed decisions, ultimately improving outcomes in cholesterol management and heart disease prevention.
Advancements in portable analyzers, smartphone-enabled devices, and digital connectivity are enhancing test accuracy and integration into broader healthcare systems, while the shift toward pharmacy-based services, home-based monitoring, and telehealth applications is broadening accessibility. At the same time, expanding adoption across emerging markets, driven by the need for affordable and scalable diagnostic solutions, is creating significant opportunities for long-term growth in the global POC lipid testing market.
Key Market highlights
Driver: Rising Cardiovascular Disease (CVD) Burden & Screening Demand
The global rise in cardiovascular disease (CVD) prevalence is a major driver of the point-of-care (POC) lipid test market, as early detection and continuous monitoring of lipid levels are essential for preventing heart attacks, strokes, and related complications. According to the World Health Organization, CVDs remain the leading cause of death worldwide, with elevated cholesterol recognized as a key modifiable risk factor. This growing disease burden has created strong demand for faster and more accessible lipid testing solutions, particularly in primary care clinics, pharmacies, and community health programs where patients can be screened without relying on centralized laboratories.
POC lipid tests enable immediate results, empowering healthcare providers to initiate timely interventions such as statin therapy or lifestyle modifications during the same consultation. The rising emphasis on preventive healthcare and routine cholesterol screening, coupled with an increasing focus on managing high-risk populations like diabetics and the elderly, further underscores the critical role of POC lipid tests in improving cardiovascular outcomes.
Restraint: Variable Accuracy and Quality Concerns
One of the key restraints hindering the growth of the point-of-care (POC) lipid test market is the variability in accuracy and quality of test results compared to centralized laboratory testing. While POC devices offer the advantage of speed and convenience, several studies have highlighted inconsistencies in lipid measurements across different brands and devices, raising questions about their reliability for definitive diagnosis or long-term patient management. Inaccurate results can lead to inappropriate treatment decisions, such as under- or over-prescription of cholesterol-lowering therapies, which undermines clinician confidence in adopting these tests widely.
Segmentation Analysis
The global point-of-care (POC) lipid test market is segmented by product type, disease indication, application, and end-user, and region.
Product Type: The consumables segment is estimated to have 64.8% of the point-of-care (POC) lipid test market share.
Consumables are the backbone of the POC lipid-test market and therefore the single largest revenue segment. Every single test run consumes a disposable item, so volumes scale directly with screening programs, chronic-disease monitoring and pharmacy/clinic throughput. They benefit from a large installed base of analyzers worldwide: once an instrument is placed, it generates repeat consumable purchases for months or years.
Manufacturers can also create “lock-in” through proprietary cartridge designs, which preserve margin even when unit price pressure exists. Distribution is broad (hospitals, primary-care clinics, pharmacies, community screening programs, and direct-to-consumer channels), so demand is diversified and less vulnerable to single-channel disruption.
The Instruments segment is estimated to have 35.2% of the point-of-care (POC) lipid test market share.
Instruments are the fastest-growing segment because technological advances and changing care models are increasing demand for new, smarter devices. Improvements in miniaturization, accuracy, sensor chemistry, connectivity (Bluetooth/cloud/EHR integration), and multiplexing (lipids + glucose/HbA1c) make modern analyzers far more attractive to clinics, pharmacies and home-care programmes than earlier generations. Instruments command higher unit selling prices and are often purchased during new clinic rollouts and by emerging-market healthcare expansion. In addition, new commercial models accelerate instrument adoption because they lower upfront cost barriers for buyers.
Instruments also benefit when manufacturers secure regulatory clearances or CLIA waivers. Risks include longer sales cycles, higher customer support/service costs and the threat of rapid obsolescence if devices aren’t continuously upgraded, but for companies and investors seeking growth and differentiation, instruments are the place to innovate and capture premium value.
Geographical Analysis
The North America point-of-care (POC) lipid test market was valued at 42.8% market share in 2024
North America is expected to remain the dominant region in the point-of-care (POC) lipid test market, holding the largest share of global revenues. The U.S. and Canada benefit from highly advanced healthcare infrastructures, widespread availability of diagnostic facilities, and strong adoption of decentralized healthcare models such as pharmacy clinics and physician offices. Cardiovascular disease remains one of the leading causes of mortality in the region, fueling continuous demand for regular cholesterol and lipid screening.
Clear regulatory guidance from the FDA and CLIA waivers, and growing awareness of preventive healthcare, contribute to the strong uptake of POC lipid tests. Additionally, the presence of major diagnostic device manufacturers, ongoing product launches, and technological advancements further reinforce the region’s dominance. With healthcare providers increasingly focused on early detection and quick decision-making at the point of care, North America is expected to retain its leadership position over the forecast period.
The Europe point-of-care (POC) lipid test market was valued at 19.4% market share in 2024
Europe accounts for a substantial share of the point-of-care (POC) Lipid Test Market, supported by its advanced healthcare infrastructure, strong regulatory frameworks, and increasing emphasis on preventive healthcare. Leading economies such as Germany, the U.K., France, and Italy are at the forefront of adoption, driven by government-backed initiatives that encourage early detection and effective management of cardiovascular risk factors. The region benefits from a well-established network of hospitals, specialty clinics, and diagnostic centers that are progressively integrating POC solutions to reduce diagnostic turnaround times and enhance patient care pathways.
At the same time, pharmacy-based testing and community-led screening programs are expanding, particularly in Western Europe, where health systems are under pressure to manage growing patient volumes efficiently. However, adoption across Eastern Europe remains comparatively slower due to infrastructure limitations, cost constraints, and varying reimbursement structures.
The Asia-Pacific point-of-care (POC) lipid test market was valued at 17.6% market share in 2024
The Asia-Pacific region is projected to register the fastest growth in the global POC lipid test market, driven by rapid urbanization, lifestyle changes, and a significant rise in cardiovascular and metabolic disorders. Countries such as China, India, Japan, and South Korea are witnessing a surge in healthcare demand as large populations grapple with rising incidences of hyperlipidemia and related conditions. Expanding healthcare infrastructure, increasing government investment in preventive health programs, and greater awareness of early diagnosis are fueling the adoption of POC lipid tests across hospitals, clinics, and even rural healthcare settings.
Moreover, growing disposable incomes, rising middle-class populations, and the proliferation of pharmacy-based health services are creating new opportunities for market penetration. The integration of digital health platforms and telemedicine in the region also supports remote lipid monitoring and chronic care management, further accelerating adoption. With strong demand in both developed and emerging economies, the Asia-Pacific region is expected to outpace other regions in growth, making it a critical focus area for manufacturers and investors.
Competitive Landscape
The major players in the point-of-care (POC) lipid test market include Abbott, F. Hoffmann-La Roche Ltd, Siemens Healthcare Private Limited (Siemens Healthineers AG), SD Biosensor, INC., ACON Laboratories, Inc., PTS Diagnostics, Woodley Equipment Company Ltd, among others.
The global Point-of-Care (POC) Lipid Test market report delivers a detailed analysis with 70 key tables, more than 66 visually impactful figures, and 195 pages of expert insights, providing a complete view of the market landscape.
The global point-of-care (POC) lipid test market reached US$ 0.68 billion in 2023, with a rise to US$ 0.72 billion in 2024, and is expected to reach US$ 1.23 billion by 2033, growing at a CAGR of 6.8% during the forecast period 2025–2033. The growing emphasis on preventive healthcare, decentralized diagnostics, and patient-centered care is reshaping the point-of-care (POC) lipid test market, as rapid testing solutions become increasingly vital for managing cardiovascular risk. By delivering immediate, reliable results outside traditional laboratories, POC lipid tests empower clinicians, pharmacists, and patients to make faster and more informed decisions, ultimately improving outcomes in cholesterol management and heart disease prevention.
Advancements in portable analyzers, smartphone-enabled devices, and digital connectivity are enhancing test accuracy and integration into broader healthcare systems, while the shift toward pharmacy-based services, home-based monitoring, and telehealth applications is broadening accessibility. At the same time, expanding adoption across emerging markets, driven by the need for affordable and scalable diagnostic solutions, is creating significant opportunities for long-term growth in the global POC lipid testing market.
Key Market highlights
- North America leads the point-of-care (POC) lipid test market, accounting for approximately 42.8% of global revenue, driven by its advanced healthcare infrastructure, strong presence of diagnostic device manufacturers, and widespread adoption of preventive healthcare practices.
- Asia-Pacific represents the fastest-growing regional market, holding about 17.6% of the share, fueled by the rising incidence of cardiovascular and metabolic disorders in countries such as China, India, Japan, and South Korea.
- Consumables remain the dominant product segment, contributing around 64.8% of market revenue. The recurring demand for test strips and cartridges ensures steady growth, as each lipid test requires a disposable component. Their widespread use in hospitals, primary-care settings, pharmacies, and community screenings underscores their critical role in driving overall market expansion.
- 2024 Market Size: US$ 0.72 Billion
- 2033 Projected Market Size: US$ 1.23 Billion
- CAGR (2025–2033): 6.8%
- North America: Largest market in 2024
- Asia Pacific: Fastest-growing market
Driver: Rising Cardiovascular Disease (CVD) Burden & Screening Demand
The global rise in cardiovascular disease (CVD) prevalence is a major driver of the point-of-care (POC) lipid test market, as early detection and continuous monitoring of lipid levels are essential for preventing heart attacks, strokes, and related complications. According to the World Health Organization, CVDs remain the leading cause of death worldwide, with elevated cholesterol recognized as a key modifiable risk factor. This growing disease burden has created strong demand for faster and more accessible lipid testing solutions, particularly in primary care clinics, pharmacies, and community health programs where patients can be screened without relying on centralized laboratories.
POC lipid tests enable immediate results, empowering healthcare providers to initiate timely interventions such as statin therapy or lifestyle modifications during the same consultation. The rising emphasis on preventive healthcare and routine cholesterol screening, coupled with an increasing focus on managing high-risk populations like diabetics and the elderly, further underscores the critical role of POC lipid tests in improving cardiovascular outcomes.
Restraint: Variable Accuracy and Quality Concerns
One of the key restraints hindering the growth of the point-of-care (POC) lipid test market is the variability in accuracy and quality of test results compared to centralized laboratory testing. While POC devices offer the advantage of speed and convenience, several studies have highlighted inconsistencies in lipid measurements across different brands and devices, raising questions about their reliability for definitive diagnosis or long-term patient management. Inaccurate results can lead to inappropriate treatment decisions, such as under- or over-prescription of cholesterol-lowering therapies, which undermines clinician confidence in adopting these tests widely.
Segmentation Analysis
The global point-of-care (POC) lipid test market is segmented by product type, disease indication, application, and end-user, and region.
Product Type: The consumables segment is estimated to have 64.8% of the point-of-care (POC) lipid test market share.
Consumables are the backbone of the POC lipid-test market and therefore the single largest revenue segment. Every single test run consumes a disposable item, so volumes scale directly with screening programs, chronic-disease monitoring and pharmacy/clinic throughput. They benefit from a large installed base of analyzers worldwide: once an instrument is placed, it generates repeat consumable purchases for months or years.
Manufacturers can also create “lock-in” through proprietary cartridge designs, which preserve margin even when unit price pressure exists. Distribution is broad (hospitals, primary-care clinics, pharmacies, community screening programs, and direct-to-consumer channels), so demand is diversified and less vulnerable to single-channel disruption.
The Instruments segment is estimated to have 35.2% of the point-of-care (POC) lipid test market share.
Instruments are the fastest-growing segment because technological advances and changing care models are increasing demand for new, smarter devices. Improvements in miniaturization, accuracy, sensor chemistry, connectivity (Bluetooth/cloud/EHR integration), and multiplexing (lipids + glucose/HbA1c) make modern analyzers far more attractive to clinics, pharmacies and home-care programmes than earlier generations. Instruments command higher unit selling prices and are often purchased during new clinic rollouts and by emerging-market healthcare expansion. In addition, new commercial models accelerate instrument adoption because they lower upfront cost barriers for buyers.
Instruments also benefit when manufacturers secure regulatory clearances or CLIA waivers. Risks include longer sales cycles, higher customer support/service costs and the threat of rapid obsolescence if devices aren’t continuously upgraded, but for companies and investors seeking growth and differentiation, instruments are the place to innovate and capture premium value.
Geographical Analysis
The North America point-of-care (POC) lipid test market was valued at 42.8% market share in 2024
North America is expected to remain the dominant region in the point-of-care (POC) lipid test market, holding the largest share of global revenues. The U.S. and Canada benefit from highly advanced healthcare infrastructures, widespread availability of diagnostic facilities, and strong adoption of decentralized healthcare models such as pharmacy clinics and physician offices. Cardiovascular disease remains one of the leading causes of mortality in the region, fueling continuous demand for regular cholesterol and lipid screening.
Clear regulatory guidance from the FDA and CLIA waivers, and growing awareness of preventive healthcare, contribute to the strong uptake of POC lipid tests. Additionally, the presence of major diagnostic device manufacturers, ongoing product launches, and technological advancements further reinforce the region’s dominance. With healthcare providers increasingly focused on early detection and quick decision-making at the point of care, North America is expected to retain its leadership position over the forecast period.
The Europe point-of-care (POC) lipid test market was valued at 19.4% market share in 2024
Europe accounts for a substantial share of the point-of-care (POC) Lipid Test Market, supported by its advanced healthcare infrastructure, strong regulatory frameworks, and increasing emphasis on preventive healthcare. Leading economies such as Germany, the U.K., France, and Italy are at the forefront of adoption, driven by government-backed initiatives that encourage early detection and effective management of cardiovascular risk factors. The region benefits from a well-established network of hospitals, specialty clinics, and diagnostic centers that are progressively integrating POC solutions to reduce diagnostic turnaround times and enhance patient care pathways.
At the same time, pharmacy-based testing and community-led screening programs are expanding, particularly in Western Europe, where health systems are under pressure to manage growing patient volumes efficiently. However, adoption across Eastern Europe remains comparatively slower due to infrastructure limitations, cost constraints, and varying reimbursement structures.
The Asia-Pacific point-of-care (POC) lipid test market was valued at 17.6% market share in 2024
The Asia-Pacific region is projected to register the fastest growth in the global POC lipid test market, driven by rapid urbanization, lifestyle changes, and a significant rise in cardiovascular and metabolic disorders. Countries such as China, India, Japan, and South Korea are witnessing a surge in healthcare demand as large populations grapple with rising incidences of hyperlipidemia and related conditions. Expanding healthcare infrastructure, increasing government investment in preventive health programs, and greater awareness of early diagnosis are fueling the adoption of POC lipid tests across hospitals, clinics, and even rural healthcare settings.
Moreover, growing disposable incomes, rising middle-class populations, and the proliferation of pharmacy-based health services are creating new opportunities for market penetration. The integration of digital health platforms and telemedicine in the region also supports remote lipid monitoring and chronic care management, further accelerating adoption. With strong demand in both developed and emerging economies, the Asia-Pacific region is expected to outpace other regions in growth, making it a critical focus area for manufacturers and investors.
Competitive Landscape
The major players in the point-of-care (POC) lipid test market include Abbott, F. Hoffmann-La Roche Ltd, Siemens Healthcare Private Limited (Siemens Healthineers AG), SD Biosensor, INC., ACON Laboratories, Inc., PTS Diagnostics, Woodley Equipment Company Ltd, among others.
The global Point-of-Care (POC) Lipid Test market report delivers a detailed analysis with 70 key tables, more than 66 visually impactful figures, and 195 pages of expert insights, providing a complete view of the market landscape.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Disease Indication
2.5. Snippet by Application
2.6. Snippet by End-User
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Cardiovascular Disease (CVD) Burden & Screening Demand
3.1.1.2. Technological Advancements
3.1.2. Restraints
3.1.2.1. Variable Accuracy and Quality Concerns
3.1.2.2. Competition from Established Lab Networks
3.1.3. Opportunity
3.1.3.1. Home/OTC and Pharmacy-based Screening
3.1.3.2. Integration with Digital Health
3.1.4. Impact Analysis
4. GLOBAL POINT-OF-CARE (POC) LIPID TEST MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with the largest-selling Brand
4.1.3. Market leaders with established products & Services
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics
5. GLOBAL POINT-OF-CARE (POC) LIPID TEST MARKET: BY PRODUCT TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
5.1.2. Market Attractiveness Index, By Product Type
5.2. Instruments*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Consumables
6. GLOBAL POINT-OF-CARE (POC) LIPID TEST MARKET: BY DISEASE INDICATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
6.1.2. Market Attractiveness Index, By Disease Indication
6.2. Hyperlipidemia*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Hypercholesterolaemia
6.4. Tangier Disease
6.5. Hyperlipoproteinemia
6.6. Familial Hypercholesterolemia
6.7. Others
7. GLOBAL POINT-OF-CARE (POC) LIPID TEST MARKET: BY APPLICATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.1.2. Market Attractiveness Index, By Application
7.2. Screening*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Monitoring
7.4. Diagnosis
8. GLOBAL POINT-OF-CARE (POC) LIPID TEST MARKET: BY END-USER
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Clinics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Diagnostic Labs
8.4. Hospitals
8.5. Home Testing
9. REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.7.1. U.S.
9.2.7.2. Canada
9.2.7.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.7.1. Germany
9.3.7.2. U.K.
9.3.7.3. France
9.3.7.4. Spain
9.3.7.5. Italy
9.3.7.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.7.1. Brazil
9.4.7.2. Argentina
9.4.7.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.7.1. China
9.5.7.2. India
9.5.7.3. Japan
9.5.7.4. South Korea
9.5.7.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
11.1. Abbott*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Product Sales
11.1.2.4. Product Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals, etc.
11.1.4.4. SWOT Analysis
11.2. F. Hoffmann-La Roche Ltd
11.3. Siemens Healthcare Private Limited (Siemens Healthineers AG)
11.4. SD Biosensor, INC.
11.5. ACON Laboratories, Inc.
11.6. PTS Diagnostics
11.7. Woodley Equipment Company Ltd (LIST NOT EXHAUSTIVE)
12. ASSUMPTIONS AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Disease Indication
2.5. Snippet by Application
2.6. Snippet by End-User
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Cardiovascular Disease (CVD) Burden & Screening Demand
3.1.1.2. Technological Advancements
3.1.2. Restraints
3.1.2.1. Variable Accuracy and Quality Concerns
3.1.2.2. Competition from Established Lab Networks
3.1.3. Opportunity
3.1.3.1. Home/OTC and Pharmacy-based Screening
3.1.3.2. Integration with Digital Health
3.1.4. Impact Analysis
4. GLOBAL POINT-OF-CARE (POC) LIPID TEST MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with the largest-selling Brand
4.1.3. Market leaders with established products & Services
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics
5. GLOBAL POINT-OF-CARE (POC) LIPID TEST MARKET: BY PRODUCT TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
5.1.2. Market Attractiveness Index, By Product Type
5.2. Instruments*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Consumables
6. GLOBAL POINT-OF-CARE (POC) LIPID TEST MARKET: BY DISEASE INDICATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
6.1.2. Market Attractiveness Index, By Disease Indication
6.2. Hyperlipidemia*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Hypercholesterolaemia
6.4. Tangier Disease
6.5. Hyperlipoproteinemia
6.6. Familial Hypercholesterolemia
6.7. Others
7. GLOBAL POINT-OF-CARE (POC) LIPID TEST MARKET: BY APPLICATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.1.2. Market Attractiveness Index, By Application
7.2. Screening*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Monitoring
7.4. Diagnosis
8. GLOBAL POINT-OF-CARE (POC) LIPID TEST MARKET: BY END-USER
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Clinics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Diagnostic Labs
8.4. Hospitals
8.5. Home Testing
9. REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.7.1. U.S.
9.2.7.2. Canada
9.2.7.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.7.1. Germany
9.3.7.2. U.K.
9.3.7.3. France
9.3.7.4. Spain
9.3.7.5. Italy
9.3.7.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.7.1. Brazil
9.4.7.2. Argentina
9.4.7.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.7.1. China
9.5.7.2. India
9.5.7.3. Japan
9.5.7.4. South Korea
9.5.7.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
11.1. Abbott*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Product Sales
11.1.2.4. Product Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals, etc.
11.1.4.4. SWOT Analysis
11.2. F. Hoffmann-La Roche Ltd
11.3. Siemens Healthcare Private Limited (Siemens Healthineers AG)
11.4. SD Biosensor, INC.
11.5. ACON Laboratories, Inc.
11.6. PTS Diagnostics
11.7. Woodley Equipment Company Ltd (LIST NOT EXHAUSTIVE)
12. ASSUMPTIONS AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
LIST OF TABLES
Table 1 Global Point-of-Care (POC) Lipid Test Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Point-of-Care (POC) Lipid Test Market Value, By Disease Indication, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Point-of-Care (POC) Lipid Test Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Point-of-Care (POC) Lipid Test Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Point-of-Care (POC) Lipid Test Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Point-of-Care (POC) Lipid Test Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Point-of-Care (POC) Lipid Test Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 8 Global Point-of-Care (POC) Lipid Test Market Value, By Disease Indication, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Point-of-Care (POC) Lipid Test Market Value, By Disease Indication, 2022-2033 (US$ Billion)
Table 10 Global Point-of-Care (POC) Lipid Test Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Point-of-Care (POC) Lipid Test Market Value, By Application, 2022-2033 (US$ Billion)
Table 12 Global Point-of-Care (POC) Lipid Test Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Point-of-Care (POC) Lipid Test Market Value, By End-User, 2022-2033 (US$ Billion)
Table 14 Global Point-of-Care (POC) Lipid Test Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Point-of-Care (POC) Lipid Test Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Point-of-Care (POC) Lipid Test Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 17 North America Point-of-Care (POC) Lipid Test Market Value, By Disease Indication, 2022-2033 (US$ Billion)
Table 18 North America Point-of-Care (POC) Lipid Test Market Value, By Application, 2022-2033 (US$ Billion)
Table 19 North America Point-of-Care (POC) Lipid Test Market Value, By End-User, 2022-2033 (US$ Billion)
Table 20 North America Point-of-Care (POC) Lipid Test Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Point-of-Care (POC) Lipid Test Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific Point-of-Care (POC) Lipid Test Market Value, By Disease Indication, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific Point-of-Care (POC) Lipid Test Market Value, By Application, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific Point-of-Care (POC) Lipid Test Market Value, By End-User, 2022-2033 (US$ Billion)
Table 25 Asia-Pacific Point-of-Care (POC) Lipid Test Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Europe Point-of-Care (POC) Lipid Test Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 27 Europe Point-of-Care (POC) Lipid Test Market Value, By Disease Indication, 2022-2033 (US$ Billion)
Table 28 Europe Point-of-Care (POC) Lipid Test Market Value, By Application, 2022-2033 (US$ Billion)
Table 29 Europe Point-of-Care (POC) Lipid Test Market Value, By End-User, 2022-2033 (US$ Billion)
Table 30 Europe Point-of-Care (POC) Lipid Test Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 South America Point-of-Care (POC) Lipid Test Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 32 South America Point-of-Care (POC) Lipid Test Market Value, By Disease Indication, 2022-2033 (US$ Billion)
Table 33 South America Point-of-Care (POC) Lipid Test Market Value, By Application, 2022-2033 (US$ Billion)
Table 34 South America Point-of-Care (POC) Lipid Test Market Value, By End-User, 2022-2033 (US$ Billion)
Table 35 South America Point-of-Care (POC) Lipid Test Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Point-of-Care (POC) Lipid Test Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Point-of-Care (POC) Lipid Test Market Value, By Disease Indication, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Point-of-Care (POC) Lipid Test Market Value, By Application, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Point-of-Care (POC) Lipid Test Market Value, By End-User, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Point-of-Care (POC) Lipid Test Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 Abbott : Overview
Table 42 Abbott : Product Portfolio
Table 43 Abbott : Key Developments
Table 44 F. Hoffmann-La Roche Ltd: Overview
Table 45 F. Hoffmann-La Roche Ltd: Product Portfolio
Table 46 F. Hoffmann-La Roche Ltd: Key Developments
Table 47 Siemens Healthcare Private Limited (Siemens Healthineers AG): Overview
Table 48 Siemens Healthcare Private Limited (Siemens Healthineers AG): Product Portfolio
Table 49 Siemens Healthcare Private Limited (Siemens Healthineers AG): Key Developments
Table 50 SD Biosensor, INC.: Overview
Table 51 SD Biosensor, INC.: Product Portfolio
Table 52 SD Biosensor, INC.: Key Developments
Table 53 ACON Laboratories, Inc.: Overview
Table 54 ACON Laboratories, Inc.: Product Portfolio
Table 55 ACON Laboratories, Inc.: Key Developments
Table 56 PTS Diagnostics: Overview
Table 57 PTS Diagnostics: Product Portfolio
Table 58 PTS Diagnostics: Key Developments
Table 59 Woodley Equipment Company Ltd: Overview
Table 60 Woodley Equipment Company Ltd: Product Portfolio
Table 61 Woodley Equipment Company Ltd: Key Developments
Table 1 Global Point-of-Care (POC) Lipid Test Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Point-of-Care (POC) Lipid Test Market Value, By Disease Indication, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Point-of-Care (POC) Lipid Test Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Point-of-Care (POC) Lipid Test Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Point-of-Care (POC) Lipid Test Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Point-of-Care (POC) Lipid Test Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Point-of-Care (POC) Lipid Test Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 8 Global Point-of-Care (POC) Lipid Test Market Value, By Disease Indication, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Point-of-Care (POC) Lipid Test Market Value, By Disease Indication, 2022-2033 (US$ Billion)
Table 10 Global Point-of-Care (POC) Lipid Test Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Point-of-Care (POC) Lipid Test Market Value, By Application, 2022-2033 (US$ Billion)
Table 12 Global Point-of-Care (POC) Lipid Test Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Point-of-Care (POC) Lipid Test Market Value, By End-User, 2022-2033 (US$ Billion)
Table 14 Global Point-of-Care (POC) Lipid Test Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Point-of-Care (POC) Lipid Test Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Point-of-Care (POC) Lipid Test Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 17 North America Point-of-Care (POC) Lipid Test Market Value, By Disease Indication, 2022-2033 (US$ Billion)
Table 18 North America Point-of-Care (POC) Lipid Test Market Value, By Application, 2022-2033 (US$ Billion)
Table 19 North America Point-of-Care (POC) Lipid Test Market Value, By End-User, 2022-2033 (US$ Billion)
Table 20 North America Point-of-Care (POC) Lipid Test Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Point-of-Care (POC) Lipid Test Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific Point-of-Care (POC) Lipid Test Market Value, By Disease Indication, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific Point-of-Care (POC) Lipid Test Market Value, By Application, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific Point-of-Care (POC) Lipid Test Market Value, By End-User, 2022-2033 (US$ Billion)
Table 25 Asia-Pacific Point-of-Care (POC) Lipid Test Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Europe Point-of-Care (POC) Lipid Test Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 27 Europe Point-of-Care (POC) Lipid Test Market Value, By Disease Indication, 2022-2033 (US$ Billion)
Table 28 Europe Point-of-Care (POC) Lipid Test Market Value, By Application, 2022-2033 (US$ Billion)
Table 29 Europe Point-of-Care (POC) Lipid Test Market Value, By End-User, 2022-2033 (US$ Billion)
Table 30 Europe Point-of-Care (POC) Lipid Test Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 South America Point-of-Care (POC) Lipid Test Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 32 South America Point-of-Care (POC) Lipid Test Market Value, By Disease Indication, 2022-2033 (US$ Billion)
Table 33 South America Point-of-Care (POC) Lipid Test Market Value, By Application, 2022-2033 (US$ Billion)
Table 34 South America Point-of-Care (POC) Lipid Test Market Value, By End-User, 2022-2033 (US$ Billion)
Table 35 South America Point-of-Care (POC) Lipid Test Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Point-of-Care (POC) Lipid Test Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Point-of-Care (POC) Lipid Test Market Value, By Disease Indication, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Point-of-Care (POC) Lipid Test Market Value, By Application, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Point-of-Care (POC) Lipid Test Market Value, By End-User, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Point-of-Care (POC) Lipid Test Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 Abbott : Overview
Table 42 Abbott : Product Portfolio
Table 43 Abbott : Key Developments
Table 44 F. Hoffmann-La Roche Ltd: Overview
Table 45 F. Hoffmann-La Roche Ltd: Product Portfolio
Table 46 F. Hoffmann-La Roche Ltd: Key Developments
Table 47 Siemens Healthcare Private Limited (Siemens Healthineers AG): Overview
Table 48 Siemens Healthcare Private Limited (Siemens Healthineers AG): Product Portfolio
Table 49 Siemens Healthcare Private Limited (Siemens Healthineers AG): Key Developments
Table 50 SD Biosensor, INC.: Overview
Table 51 SD Biosensor, INC.: Product Portfolio
Table 52 SD Biosensor, INC.: Key Developments
Table 53 ACON Laboratories, Inc.: Overview
Table 54 ACON Laboratories, Inc.: Product Portfolio
Table 55 ACON Laboratories, Inc.: Key Developments
Table 56 PTS Diagnostics: Overview
Table 57 PTS Diagnostics: Product Portfolio
Table 58 PTS Diagnostics: Key Developments
Table 59 Woodley Equipment Company Ltd: Overview
Table 60 Woodley Equipment Company Ltd: Product Portfolio
Table 61 Woodley Equipment Company Ltd: Key Developments
LIST OF FIGURES
Figure 1 Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Point-of-Care (POC) Lipid Test Market Share, By Product Type, 2024 & 2033 (%)
Figure 3 Global Point-of-Care (POC) Lipid Test Market Share, By Disease Indication, 2024 & 2033 (%)
Figure 4 Global Point-of-Care (POC) Lipid Test Market Share, By Application, 2024 & 2033 (%)
Figure 5 Global Point-of-Care (POC) Lipid Test Market Share, By End-User, 2024 & 2033 (%)
Figure 6 Global Point-of-Care (POC) Lipid Test Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Point-of-Care (POC) Lipid Test Market Y-o-Y Growth, By Product Type, 2023-2033 (%)
Figure 8 Instruments Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 9 Consumables Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 10 Global Point-of-Care (POC) Lipid Test Market Y-o-Y Growth, By Disease Indication, 2023-2033 (%)
Figure 11 Hyperlipidemia Disease Indication in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 12 Hypercholesterolaemia Disease Indication in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 13 Tangier Disease Disease Indication in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 14 Hyperlipoproteinemia Disease Indication in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 15 Familial Hypercholesterolemia Disease Indication in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 16 Others Disease Indication in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 17 Global Point-of-Care (POC) Lipid Test Market Y-o-Y Growth, By Application, 2023-2033 (%)
Figure 18 Screening Application in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 19 Monitoring Application in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 20 Diagnosis Application in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 21 Global Point-of-Care (POC) Lipid Test Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 22 Clinics End-User in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 23 Diagnostic Labs End-User in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 24 Hospitals End-User in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 25 Home Testing End-User in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 26 Global Point-of-Care (POC) Lipid Test Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 27 North America Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 28 North America Point-of-Care (POC) Lipid Test Market Share, By Product Type, 2024 & 2033 (%)
Figure 29 North America Point-of-Care (POC) Lipid Test Market Share, By Disease Indication, 2024 & 2033 (%)
Figure 30 North America Point-of-Care (POC) Lipid Test Market Share, By Application, 2024 & 2033 (%)
Figure 31 North America Point-of-Care (POC) Lipid Test Market Share, By End-User, 2024 & 2033 (%)
Figure 32 North America Point-of-Care (POC) Lipid Test Market Share, By Country, 2024 & 2033 (%)
Figure 33 Asia-Pacific Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 34 Asia-Pacific Point-of-Care (POC) Lipid Test Market Share, By Product Type, 2024 & 2033 (%)
Figure 35 Asia-Pacific Point-of-Care (POC) Lipid Test Market Share, By Disease Indication, 2024 & 2033 (%)
Figure 36 Asia-Pacific Point-of-Care (POC) Lipid Test Market Share, By Application, 2024 & 2033 (%)
Figure 37 Asia-Pacific Point-of-Care (POC) Lipid Test Market Share, By End-User, 2024 & 2033 (%)
Figure 38 Asia-Pacific Point-of-Care (POC) Lipid Test Market Share, By Country, 2024 & 2033 (%)
Figure 39 Europe Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 40 Europe Point-of-Care (POC) Lipid Test Market Share, By Product Type, 2024 & 2033 (%)
Figure 41 Europe Point-of-Care (POC) Lipid Test Market Share, By Disease Indication, 2024 & 2033 (%)
Figure 42 Europe Point-of-Care (POC) Lipid Test Market Share, By Application, 2024 & 2033 (%)
Figure 43 Europe Point-of-Care (POC) Lipid Test Market Share, By End-User, 2024 & 2033 (%)
Figure 44 Europe Point-of-Care (POC) Lipid Test Market Share, By Country, 2024 & 2033 (%)
Figure 45 South America Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 46 South America Point-of-Care (POC) Lipid Test Market Share, By Product Type, 2024 & 2033 (%)
Figure 47 South America Point-of-Care (POC) Lipid Test Market Share, By Disease Indication, 2024 & 2033 (%)
Figure 48 South America Point-of-Care (POC) Lipid Test Market Share, By Application, 2024 & 2033 (%)
Figure 49 South America Point-of-Care (POC) Lipid Test Market Share, By End-User, 2024 & 2033 (%)
Figure 50 South America Point-of-Care (POC) Lipid Test Market Share, By Country, 2024 & 2033 (%)
Figure 51 Middle East and Africa Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 52 Middle East and Africa Point-of-Care (POC) Lipid Test Market Share, By Product Type, 2024 & 2033 (%)
Figure 53 Middle East and Africa Point-of-Care (POC) Lipid Test Market Share, By Disease Indication, 2024 & 2033 (%)
Figure 54 Middle East and Africa Point-of-Care (POC) Lipid Test Market Share, By Application, 2024 & 2033 (%)
Figure 55 Middle East and Africa Point-of-Care (POC) Lipid Test Market Share, By End-User, 2024 & 2033 (%)
Figure 56 Abbott : Financials
Figure 57 F. Hoffmann-La Roche Ltd: Financials
Figure 58 Siemens Healthcare Private Limited (Siemens Healthineers AG): Financials
Figure 59 SD Biosensor, INC.: Financials
Figure 60 ACON Laboratories, Inc.: Financials
Figure 61 PTS Diagnostics: Financials
Figure 62 Woodley Equipment Company Ltd: Financials
Figure 1 Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Point-of-Care (POC) Lipid Test Market Share, By Product Type, 2024 & 2033 (%)
Figure 3 Global Point-of-Care (POC) Lipid Test Market Share, By Disease Indication, 2024 & 2033 (%)
Figure 4 Global Point-of-Care (POC) Lipid Test Market Share, By Application, 2024 & 2033 (%)
Figure 5 Global Point-of-Care (POC) Lipid Test Market Share, By End-User, 2024 & 2033 (%)
Figure 6 Global Point-of-Care (POC) Lipid Test Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Point-of-Care (POC) Lipid Test Market Y-o-Y Growth, By Product Type, 2023-2033 (%)
Figure 8 Instruments Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 9 Consumables Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 10 Global Point-of-Care (POC) Lipid Test Market Y-o-Y Growth, By Disease Indication, 2023-2033 (%)
Figure 11 Hyperlipidemia Disease Indication in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 12 Hypercholesterolaemia Disease Indication in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 13 Tangier Disease Disease Indication in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 14 Hyperlipoproteinemia Disease Indication in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 15 Familial Hypercholesterolemia Disease Indication in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 16 Others Disease Indication in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 17 Global Point-of-Care (POC) Lipid Test Market Y-o-Y Growth, By Application, 2023-2033 (%)
Figure 18 Screening Application in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 19 Monitoring Application in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 20 Diagnosis Application in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 21 Global Point-of-Care (POC) Lipid Test Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 22 Clinics End-User in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 23 Diagnostic Labs End-User in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 24 Hospitals End-User in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 25 Home Testing End-User in Global Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 26 Global Point-of-Care (POC) Lipid Test Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 27 North America Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 28 North America Point-of-Care (POC) Lipid Test Market Share, By Product Type, 2024 & 2033 (%)
Figure 29 North America Point-of-Care (POC) Lipid Test Market Share, By Disease Indication, 2024 & 2033 (%)
Figure 30 North America Point-of-Care (POC) Lipid Test Market Share, By Application, 2024 & 2033 (%)
Figure 31 North America Point-of-Care (POC) Lipid Test Market Share, By End-User, 2024 & 2033 (%)
Figure 32 North America Point-of-Care (POC) Lipid Test Market Share, By Country, 2024 & 2033 (%)
Figure 33 Asia-Pacific Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 34 Asia-Pacific Point-of-Care (POC) Lipid Test Market Share, By Product Type, 2024 & 2033 (%)
Figure 35 Asia-Pacific Point-of-Care (POC) Lipid Test Market Share, By Disease Indication, 2024 & 2033 (%)
Figure 36 Asia-Pacific Point-of-Care (POC) Lipid Test Market Share, By Application, 2024 & 2033 (%)
Figure 37 Asia-Pacific Point-of-Care (POC) Lipid Test Market Share, By End-User, 2024 & 2033 (%)
Figure 38 Asia-Pacific Point-of-Care (POC) Lipid Test Market Share, By Country, 2024 & 2033 (%)
Figure 39 Europe Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 40 Europe Point-of-Care (POC) Lipid Test Market Share, By Product Type, 2024 & 2033 (%)
Figure 41 Europe Point-of-Care (POC) Lipid Test Market Share, By Disease Indication, 2024 & 2033 (%)
Figure 42 Europe Point-of-Care (POC) Lipid Test Market Share, By Application, 2024 & 2033 (%)
Figure 43 Europe Point-of-Care (POC) Lipid Test Market Share, By End-User, 2024 & 2033 (%)
Figure 44 Europe Point-of-Care (POC) Lipid Test Market Share, By Country, 2024 & 2033 (%)
Figure 45 South America Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 46 South America Point-of-Care (POC) Lipid Test Market Share, By Product Type, 2024 & 2033 (%)
Figure 47 South America Point-of-Care (POC) Lipid Test Market Share, By Disease Indication, 2024 & 2033 (%)
Figure 48 South America Point-of-Care (POC) Lipid Test Market Share, By Application, 2024 & 2033 (%)
Figure 49 South America Point-of-Care (POC) Lipid Test Market Share, By End-User, 2024 & 2033 (%)
Figure 50 South America Point-of-Care (POC) Lipid Test Market Share, By Country, 2024 & 2033 (%)
Figure 51 Middle East and Africa Point-of-Care (POC) Lipid Test Market Value, 2022-2033 (US$ Billion)
Figure 52 Middle East and Africa Point-of-Care (POC) Lipid Test Market Share, By Product Type, 2024 & 2033 (%)
Figure 53 Middle East and Africa Point-of-Care (POC) Lipid Test Market Share, By Disease Indication, 2024 & 2033 (%)
Figure 54 Middle East and Africa Point-of-Care (POC) Lipid Test Market Share, By Application, 2024 & 2033 (%)
Figure 55 Middle East and Africa Point-of-Care (POC) Lipid Test Market Share, By End-User, 2024 & 2033 (%)
Figure 56 Abbott : Financials
Figure 57 F. Hoffmann-La Roche Ltd: Financials
Figure 58 Siemens Healthcare Private Limited (Siemens Healthineers AG): Financials
Figure 59 SD Biosensor, INC.: Financials
Figure 60 ACON Laboratories, Inc.: Financials
Figure 61 PTS Diagnostics: Financials
Figure 62 Woodley Equipment Company Ltd: Financials
